

April 24th, 2018

Cell Innovation Partners Limited

Allergan Completes Elastagen Acquisition

Cell Innovation Partners Limited (hereinafter, "CIP") sold its share of Elastagen Pty Ltd (hereinafter, "Elastagen") to Allergan plc (hereinafter, "Allergan") as of April 6th 2018. This transaction is associated with Allergan's acquisition of Elastagen for an upfront payment of US\$95 million plus contingent commercial payments.

Elastagen is a clinical stage company developing medical device products based on recombinant human tropoelastin, the precursor of elastin which is a key component of youthful skin. Elastagen's tropoelastin is identical to that present in human tissue, and has many potential clinical applications, including treatment for acne scars, stretch marks, aesthetic skin repair and surgical wound repair.

Going forward CIP will support the value creation of its portfolio companies through providing our expertise in regenerative medicine.

Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global biopharmaceutical company. Allergan is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologics, surgical and regenerative medicine products for patients around the world. Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology and anti-infective therapeutic categories.

For more information, please go to www.allergan.com

Contact information:

Cell Innovation Partners Limited

<http://www.cell-ip.com/en>

Kazunobu Nishimura

Email: contact@cell-ip.com